Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: Peeking into China’s healthcare deals

China’s hospital landscape is rapidly changing as operators and owners respond to shifting policy incentives, an aging population, the opportunity to serve Tier 2 and 3 cities, and shifts in consumer preferences.

One result: growing m&a activity, with assets changing hands in deals involving China’s TTC Franchise Clinics; Beijing Remote Heart Community Hospital; Chengdu New Century Women’s and Children’s Hospital; and Renyi Hospital Company. Some transactions are driven by the desire to consolidate holdings in key cities; others are deals struck to migrate from non-profit to for profit status.

We also are seeing specialty deals in segments such as dental, fertility clinics, eldercare, and nursing homes. Examples include Harmonicare Medical; OUE Lippo Healthcare; Pine Care/Yada JV; and China Cord Blood. These transactions reflect consumer and investor responses to behavioural and demographic shifts: delayed child-bearing has created demand for fertility support; China’s aging population needs more eldercare and nursing homes. We anticipate that such thematic-driven deals will continue.

Beyond these deals, it is important to note the mindset shift among owners of healthcare assets in China. We are seeing Chinese healthcare operators continue to invest in upgrading their capabilities, their physician mix, and their technology base, for example streamlined electronic health records and pharmacy systems. Big thinking is taking place, including ways to capture genetic information and link that to patient records and population health systems – with all the privacy, regulatory and ethical ramifications involved. Combined with growing investment in artificial intelligence and machine learning systems for diagnostic care, important shifts are occurring in China’s care system.

These early stage shifts in China’s treatment landscape in terms of ownership, quality of outcomes, technology systems, and patient preferences are catching investor attention, both domestic and foreign. Many of the Chinese owners/ operators we talk to want technology and capability partnerships to differentiate themselves further especially in a world in which care starts to become decentralised due to technologies like telemedicine and remote diagnostics.

A number are turning to Singapore, the US and Britain for potential partners. These partnerships can range from systems design to ongoing capability transfers to equity co-investment. In rare cases, we have also seen Chinese investors consider outright acquisition of US assets to cement those ties rather than simply do a co-branding deal.

What the future holds is largely dependent on patient flows and policy makers. As US healthcare is increasingly expensive, medical tourism from the US to Asia is likely to rise if US consumers are confident they will receive equivalent treatment outcomes. One Beijing hospital is hoping to provide that level of comfort by having its medical tourism work overseen by an US-based (Ohio) doctor affiliated with the hospital.

We believe there is a largely unexplored option to seize this opportunity. It involves building hospitals and care facilities on both sides of the Pacific, and forming a single global network that allows for profit sharing, patient record sharing, HCP talent exchanges, use of facilities irrespective of location, and cross-referrals, for example. Such a step could help unlock a different end-game for these partnerships rather than one that simply focuses on cash transfers for technology rights. Reinventing the care model in both markets can be the profitable prize especially given forecasts for population growth.

That said, for Chinese hospitals and treatment facilities, the in-country patient pool will always be the dominant source of revenues. China’s aging population, rising purchasing power, and gender mix will force shifts in care, e.g. dental, beauty treatments, home care and fertility treatments. Be that as it may, innovations that draw upon some of the best practices from global markets can also serve the domestic Chinese consumer and patient well.

Those options and others await investors who can partner with Chinese health organisations to reinvent the care model. Feel free to contact me or my consulting colleagues here in Asia to learn more.

Jude Uzonwanne is a principal with IQVIA, the world's largest pure play healthcare advisory services company. He provides strategy and transaction advice to clients in Asia Pacific region. He can be reached at jude.uzonwanne@iqvia.com.

Posted on: 13/08/2018 UTC+08:00


News

Bumrungrad Hospital, Thailand’s second-largest listed hospital operator, continues to expand its investment. It will take a 30% stake in Singapore’s iDoctor for US$3 million and will invest Bt270 million (US$8.2 million) in a wellness center clinic under the project name Project Beta of Vitallife.
Ping An Good Doctor, UMP Healthcare and Zheng He Health and Medical Resources have announced their strategic cooperation. The three parties will make full use of their respective advantages and resources to jointly build an online and offline family doctor services network and realise the shared vision of "providing each family with a trusted family doctor". This cooperation also aims to help the government to achieve the goal of promoting and developing family doctor services across China.
HuiyiHuiying (HY), a leading medical imaging artificial intelligence company in China, has closed a strategic investment led by Intel Capital with participation of Beijing Singularity Power Investment Fund (SPC), marking the first investments by the firms in the medical AI sector in China. HY will use the funding proceeds to support its business development, product innovation and talent recruitment initiatives.
Australian hearing implant manufacturer Cochlear and GN, the global leader in intelligent audio solutions, have signed a new agreement to expand their Smart Hearing Alliance collaboration significantly.
China's leading clinical genomics testing company, Berry Genomics, and Prenetics – the leading consumer digital health and genetics testing company in southeast Asia and Europe – will establish a joint venture company that will deliver transformative consumer digital health and genetics testing services in mainland China.
Ping An Good Doctor (PAGD) has announced that the first commercially operational unmanned clinic in China, which it researched and developed, "One-minute Clinics" has been formally revealed in a scenic area in Wuzhen. It will provide a high-speed, convenient, one-stop shop for medical and healthcare services for nearby residents, visitors to the scenic area and guests of the 2018 World Internet Conference.
The Morrison government has announced a further A$34.8 million (US$24.7 million) investment in renal dialysis in remote areas.
Rici Healthcare, a private general medical services group in the Yangtze River Delta, has acquired stakes in a number of companies for Rmb68 million (US$9.8 million by acquiring the medical business of Wang Dejun.



Analysis

The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.
For too many companies, a stock market flotation is the be all and end all. Chief executives have spent months on roadshows, locked up with bankers and lawyers. Understandably they think that they can now rest on their laurels.
Today is the launch of Asia Pacific’s first Life Sciences Centre of Excellence. It is part of global management consulting firm LEK Consulting’s Healthcare Insights Centre and aims to drive thought leadership and innovation to elevate the life sciences ecosystem in Singapore and the region.
Dementia remains one of the biggest chronic medical issues to face families. A determination to treat the illness is a challenge that Charles Stacey, president and CEO of Singapore-based Cerecin, has grasped with both hands.
Abrar Mir is that rare thing in the healthcare sector: a voice of reason. It notable that when he speaks at conferences, the chatter outside the auditorium diminishes and seats suddenly become hard to find. Part of this is thanks to his position as managing partner of Singapore-based private equity fund Quadria Healthcare, which he co-founded in 2012. But as much of it is due to his quiet authority and passion, as it is to the US$1.5 billion he has under management across the Asia Pacific region.
SOHO Global Health was founded in 1946 in Jakarta by Tan Tjhoen Lim as an injectables-focused pharmaceutical company. Today it is one of the largest pharmaceutical manufacturing and distribution businesses in Indonesia with a network that covers more than 80% of the hospitals and 90% of the pharmacies in the country.
Anupa Naik speaks nineteen to the dozen. The chief executive of Symple Wellness, a healthcare company set up in Singapore in July last year as an offshoot of the family office AJ Capital, has barely stood still since then, and shows no sign of stopping any time soon.
After listing on the Hong Kong Stock Exchange at the beginning of May, Ping An Healthcare and Technology, formerly known as Good Doctor, shows no sign of slowing down.
my images

Podcasts

HealthInvestor Asia twitter feed